121 related articles for article (PubMed ID: 18467723)
1. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
Kozuch PS; Rocha-Lima CM; Dragovich T; Hochster H; O'Neil BH; Atiq OT; Pipas JM; Ryan DP; Lenz HJ
J Clin Oncol; 2008 May; 26(14):2320-6. PubMed ID: 18467723
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH
J Clin Oncol; 2006 Nov; 24(31):5025-33. PubMed ID: 17075122
[TBL] [Abstract][Full Text] [Related]
3. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Ryan DP; O'Neil BH; Supko JG; Rocha Lima CM; Dees EC; Appleman LJ; Clark J; Fidias P; Orlowski RZ; Kashala O; Eder JP; Cusack JC
Cancer; 2006 Dec; 107(11):2688-97. PubMed ID: 17075878
[TBL] [Abstract][Full Text] [Related]
4. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Scagliotti GV; Germonpré P; Bosquée L; Vansteenkiste J; Gervais R; Planchard D; Reck M; De Marinis F; Lee JS; Park K; Biesma B; Gans S; Ramlau R; Szczesna A; Makhson A; Manikhas G; Morgan B; Zhu Y; Chan KC; von Pawel J
Lung Cancer; 2010 Jun; 68(3):420-6. PubMed ID: 19692142
[TBL] [Abstract][Full Text] [Related]
7. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Ning YM; He K; Dagher R; Sridhara R; Farrell AT; Justice R; Pazdur R
Oncology (Williston Park); 2007 Nov; 21(12):1503-8; discussion 1511, 1513, 1516 passim. PubMed ID: 18077994
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Lynch TJ; Fenton D; Hirsh V; Bodkin D; Middleman EL; Chiappori A; Halmos B; Favis R; Liu H; Trepicchio WL; Eton O; Shepherd FA
J Thorac Oncol; 2009 Aug; 4(8):1002-9. PubMed ID: 19633475
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
[TBL] [Abstract][Full Text] [Related]
14. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Bajetta E; Di Bartolomeo M; Mariani L; Cassata A; Artale S; Frustaci S; Pinotti G; Bonetti A; Carreca I; Biasco G; Bonaglia L; Marini G; Iannelli A; Cortinovis D; Ferrario E; Beretta E; Lambiase A; Buzzoni R;
Cancer; 2004 Jan; 100(2):279-87. PubMed ID: 14716761
[TBL] [Abstract][Full Text] [Related]
16. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
[TBL] [Abstract][Full Text] [Related]
17. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
18. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
[TBL] [Abstract][Full Text] [Related]
19. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]